ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sumitomo Pharma and Gilead Sciences side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Sumitomo PharmaGilead Sciences
studies on the registry273738
open to participants now932
phase 3 studies under way232
reach primary completion within a year419
programswith a study of their own in two years432

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSumitomo PharmaGilead Sciences
Phase 100%

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%
Phase 2

Sumitomo Pharma: 4 of its 4 programs at phase 2

  1. nuvisertibphase 2
  2. enzomenibphase 2
  3. DSP-1083phase 2
  4. DSP-3077phase 2
100%

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%
Phase 300%

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. seladelparphase 3
  4. axicabtagene ciloleucelphase 3
  5. GS-3242phase 3

and 10 more — sign in to see them all

47%
Approved, new studies00%

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sumitomo Pharma2 readouts · 0 phase 3·····

Sumitomo Pharma, Apr ’27: 1 program whose next study reaches primary completion

  1. nuvisertibphase 2 · Apr 30 · NCT04176198
·

Sumitomo Pharma, Jun ’27: 1 program whose next study reaches primary completion

  1. enzomenibphase 2 · Jun 30 · NCT04988555
····
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sumitomo Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionSumitomo PharmaGilead Sciences
Neoplasmsboth · compare here

Sumitomo Pharma in Neoplasms: 1 program

  1. nuvisertibphase 2

Their studies: Sumitomo Pharma’s studies of Neoplasms in search

Gilead Sciences in Neoplasms: 2 programs

  1. lurbinectedinphase 3
  2. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Sumitomo Pharma 1 of 4 · Gilead Sciences 16 of 32 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.